Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

•We report an extended OS follow-up to the MONALEESA-3 trial (median, 56.3 months).•mOS was longer for the ribociclib arm versus the placebo arm: 53.7 versus 41.5 months (HR, 0.73; 95% CI 0.59-0.90).•OS benefit was observed with ribociclib in the first- and second-line settings.•No apparent drug–drug interaction between ribociclib and fulvestrant or new safety signals were observed.